Lixte Biotechnology Holdings Stock Retained Earnings

LIXT Stock  USD 3.52  1.26  55.75%   
Lixte Biotechnology Holdings fundamentals help investors to digest information that contributes to Lixte Biotechnology's financial success or failures. It also enables traders to predict the movement of Lixte Stock. The fundamental analysis module provides a way to measure Lixte Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lixte Biotechnology stock.
Retained Earnings is likely to gain to about (46.1 M) in 2024.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Lixte Retained Earnings Analysis

Lixte Biotechnology's Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.

Lixte Biotechnology Retained Earnings

(46.06 Million)

Retained Earnings

 = 

Beginning RE + Income

-

Dividends

More About Retained Earnings | All Equity Analysis

Current Lixte Biotechnology Retained Earnings

    
  (48.48 M)  
Most of Lixte Biotechnology's fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lixte Biotechnology Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Lixte Retained Earnings Driver Correlations

Understanding the fundamental principles of building solid financial models for Lixte Biotechnology is extremely important. It helps to project a fair market value of Lixte Stock properly, considering its historical fundamentals such as Retained Earnings. Since Lixte Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lixte Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lixte Biotechnology's interrelated accounts and indicators.
0.650.96-0.97-0.760.760.241.0-0.30.46-0.56-0.83-0.660.350.580.950.94-0.75-0.110.01
0.650.63-0.63-0.720.70.460.65-0.190.41-0.35-0.7-0.470.720.370.660.65-0.74-0.23-0.07
0.960.63-1.0-0.840.860.210.96-0.40.42-0.56-0.88-0.710.340.640.980.98-0.83-0.35-0.27
-0.97-0.63-1.00.83-0.85-0.22-0.970.38-0.430.60.860.72-0.34-0.63-0.97-0.970.820.320.23
-0.76-0.72-0.840.83-0.99-0.45-0.750.38-0.510.30.910.71-0.69-0.41-0.81-0.820.890.590.43
0.760.70.86-0.85-0.990.430.76-0.440.46-0.34-0.89-0.680.650.490.830.85-0.9-0.64-0.49
0.240.460.21-0.22-0.450.430.240.130.66-0.13-0.22-0.010.480.040.160.17-0.3-0.12-0.06
1.00.650.96-0.97-0.750.760.24-0.290.46-0.56-0.83-0.660.340.580.950.94-0.75-0.10.01
-0.3-0.19-0.40.380.38-0.440.13-0.290.160.420.30.18-0.21-0.66-0.45-0.460.620.510.38
0.460.410.42-0.43-0.510.460.660.460.16-0.18-0.51-0.540.29-0.130.410.4-0.310.0-0.02
-0.56-0.35-0.560.60.3-0.34-0.13-0.560.42-0.180.270.370.06-0.57-0.54-0.540.50.140.08
-0.83-0.7-0.880.860.91-0.89-0.22-0.830.3-0.510.270.8-0.62-0.35-0.88-0.890.830.370.27
-0.66-0.47-0.710.720.71-0.68-0.01-0.660.18-0.540.370.8-0.3-0.05-0.7-0.70.620.30.22
0.350.720.34-0.34-0.690.650.480.34-0.210.290.06-0.62-0.30.060.350.35-0.62-0.3-0.09
0.580.370.64-0.63-0.410.490.040.58-0.66-0.13-0.57-0.35-0.050.060.660.67-0.59-0.38-0.29
0.950.660.98-0.97-0.810.830.160.95-0.450.41-0.54-0.88-0.70.350.661.0-0.83-0.3-0.22
0.940.650.98-0.97-0.820.850.170.94-0.460.4-0.54-0.89-0.70.350.671.0-0.84-0.34-0.27
-0.75-0.74-0.830.820.89-0.9-0.3-0.750.62-0.310.50.830.62-0.62-0.59-0.83-0.840.520.4
-0.11-0.23-0.350.320.59-0.64-0.12-0.10.510.00.140.370.3-0.3-0.38-0.3-0.340.520.89
0.01-0.07-0.270.230.43-0.49-0.060.010.38-0.020.080.270.22-0.09-0.29-0.22-0.270.40.89
Click cells to compare fundamentals
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
Competition

Based on the latest financial disclosure, Lixte Biotechnology Holdings has a Retained Earnings of (48.48 Million). This is 105.21% lower than that of the Biotechnology sector and 150.04% lower than that of the Health Care industry. The retained earnings for all United States stocks is 100.52% higher than that of the company.

Lixte Retained Earnings Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lixte Biotechnology's direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lixte Biotechnology could also be used in its relative valuation, which is a method of valuing Lixte Biotechnology by comparing valuation metrics of similar companies.
Lixte Biotechnology is currently under evaluation in retained earnings category among related companies.

Lixte Fundamentals

About Lixte Biotechnology Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Lixte Biotechnology Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lixte Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lixte Biotechnology Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2024
Retained Earnings-48.5 M-46.1 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Lixte Biotechnology is a strong investment it is important to analyze Lixte Biotechnology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lixte Biotechnology's future performance. For an informed investment choice regarding Lixte Stock, refer to the following important reports:
Check out Lixte Biotechnology Piotroski F Score and Lixte Biotechnology Altman Z Score analysis.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for Lixte Stock analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Bonds Directory
Find actively traded corporate debentures issued by US companies
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Is Lixte Biotechnology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lixte Biotechnology. If investors know Lixte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lixte Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.66)
Return On Assets
(0.64)
Return On Equity
(1.11)
The market value of Lixte Biotechnology is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lixte Biotechnology's market value can be influenced by many factors that don't directly affect Lixte Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lixte Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lixte Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lixte Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.